Pharsight

Suprenza is owned by Citius Pharms.

Suprenza contains Phentermine Hydrochloride.

Suprenza has a total of 1 drug patent out of which 0 drug patents have expired.

Suprenza was authorised for market use on 13 June, 2011.

Suprenza is available in tablet, orally disintegrating;oral dosage forms.

The generics of Suprenza are possible to be released after 14 March, 2029.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8440170	November, 2015	Terminated-Adverse Judgment	ALPEX PHARMA	Erich Spangenberg

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440170	CITIUS PHARMS	Orally disintegrating tablets with speckled appearance	Mar, 2029 (5 years from now)

Market Authorisation Date: 13 June, 2011

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg and 30 mg	19 Oct, 2012	1	28 Jun, 2017	23 Jul, 2018	Deferred
37.5 mg	22 Mar, 2013	1	28 Jun, 2017	23 Jul, 2018	Deferred

Strength	Dosage	Availability
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
30MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
37.5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued